GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association’s (ADA) Scientific Sessions. Details on the fireside chat are as follows: Title:Piper Sandler Virtual Obesity Investor Day  Present ...

NEW YORK, June 20, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=86302&from=4CLASS PERIOD: December 1, 2023 to April ...

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=85778&from=3  CLASS PERIOD: December 1, 2023 ...

GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association's (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024. Details for the oral presentations are as follows: Session Title:Leveling Up Incretin-Based Therapy in T ...

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 5, 2024. If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

Low-priced stocks under $10 can be explosively awarding.That is, if you spot the right one at the right time with the right catalyst. Look at Advanced Micro Devices (NASDAQ:AMD). Not too long ago, AMD traded at about $10 a share as chip demand began to heat back up. Then, as the artificial intelligence (AI) boom hit, AMD made its way above $200 a share. Netflix (NASDAQ:NFLX) once traded at $10 as the movie rental business started to see a massive transformation from the old Blockbuster model. Years later, i ...

LAS VEGAS, June 11, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sigma, has launched a new service named "ALT5 Settlement Platform" aimed at the untapped Global Digital Content Creation Market.According to JanOne, ALT5 Settlement Platform enables Digital Platforms with the ability instantaneously to pay all content creators in a cryptocurrency of their choice through ALT5 Settle ...

NEW YORK, June 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=83249&from=4CLASS PERIOD: December 1, 2023 to April ...

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-sub ...

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=82889&from=3 CLASS PERIOD: December 1, 2023 t ...